Background: Recent studies have shown that immunocompetent cells synthesize and express growth hormone (GH), growth hormone receptors (GH-R), insulin-like growth factor I (IGF-I), IGF-I receptors (IGF-I-R) and different insulin-like growth factor binding proteins (IGFBPs). The aim of the current study was to evaluate the regulation of IGFBP and IGF-I secretion from immunocompetent cells by different mitogens. Methods/Results: We studied the in vitro secretion pattern of IGFBPs and IGF-I from human peripheral blood mononuclear cells (PBMC), derived from 10 normal adults and 8 GH-deficient patients with adult onset. In serum-free conditioned medium of unstimulated PBMC, derived from normal adults, Western ligand blotting (1D-WLB) revealed a 24-kD, a 34-kD and a 39/43-kD doublet band to be most prominent. According to their molecular weight and two-dimensional Western ligand blot analysis (2D-WLB), these bands are deglycosylated IGFBP-4, IGFBP-2 and IGFBP-3, respectively. When the cells were treated with the T-cell mitogen phytohemagglutinin (PHA) (10 µg/ml), a differential stimulation of IGFBPs was found with a 2.57 ± 0.48-fold increase of IGFBP-4 (p < 0.01), a 1.55 ± 0.13-fold increase of IGFBP-2 (p < 0.01), and a 1.35 ± 0.19-fold increase of IGFBP-3 (n.s.). In contrast, treatment with the B-cell mitogen pokeweed mitogen (PWM) (10 µg/ml) caused only a modest 1.40 ± 0.07-fold increase of IGFBP-4 (p < 0.01). Treatment with rhGH (100 ng/ml) or rhIGF-I (200 ng/ml) caused no significant induction of any specific band, respectively. In contrast to the secretion pattern of IGFBPs, IGF-I secretion of the PBMC was not stimulated by either PHA or PWM, but showed a significant increase after GH incubation (p < 0.01). A similar differentiated secretion pattern of IGFBPs and IGF-I was also observed in the conditioned medium of PBMC, derived from GH-deficient patients. Conclusion: In summary, at least three different IGFBPs are secreted by human PBMC. Secretion of IGFBPs by PBMC is differentially regulated by different lymphocyte mitogens. Secretion of IGFBPs by PBMC is independent of GH or IGF-I, whereas the secretion of IGF-I is stimulated by GH. PBMC derived from normal adults and GH-deficient patients show similar patterns of IGF-I and IGFBPs secretion, thus indicating that the paracrine/autocrine IGF-I–IGFBPs interactions of the PBMC are not altered by pituitary GH deficiency.

Keywords:
Insulin-like growth factor, IGF-I, IGF-binding proteins, Mononuclear cells
1.
Clark R: The somatogenic hormones and insulin-like growth factor-1: Stimulators of lymphopoiesis and immune function. Endocr Rev 1997;18:157–179.
2.
Kooijman R, Hooghe-Peters EL, Hooghe R: Prolactin, growth hormone, and insulin-like growth factor-I in the immune system. Adv Immunol 1996;63:377–454.
3.
Auernhammer CJ, Strasburger CJ: Effects of growth hormone and insulin-like growth factor on the immune system. Eur J Endocrinol 1995;133:635–645.
4.
Auernhammer CJ, Bidlingmaier M, Strasburger CJ: Growth hormone and the immune system; in Bengtsson BA (ed): Growth Hormone, ed 1. Norwell, Kluwer Academic Publishers, 1999, chap 13, pp 189–225.
5.
Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 1995;16:3–34.
6.
Kelley KM, Oh Y, Gargosky E, Gicev Z, Matsumoto T, HWA V, Ng L, Simpson DM, Rosenfeld RG: Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 1996;28:619–637.
7.
Abboud SL, Bethel CR, Aron DC: Secretion of insulin-like growth factor I and insulin-like growth factor-binding proteins by murine bone marrow stromal cells. J Clin Invest 1991;88:470–475.
8.
Grellier P, Yee D, Gonzalez M, Abboud SL: Characterization of insulin-like growth factor binding proteins (IGFBP) and regulation of IGFBP-4 in bone marrow stromal cells. Br J Haematol 1995;90:249–257.
9.
Li YM, Arkins S, McCusker RH Jr, Donovan SM, Liu Q, Jayaraman S, Dantzer R, Kelley KW: Macrophages synthesize and secrete a 25-kilodalton protein that binds insulin-like growth factor-I. J Immunol 1996;156:64–72.
10.
Neely EK, Smith SD, Rosenfeld RG: Human leukemic T and B lymphoblasts produce insulin-like growth factor binding proteins 2 and 4. Acta Endocrinol 1991;124:707–714.
11.
Yang Y, Hoeflich A, Kessler U, Barenton B, Blum W, Schwarz HP, Kiess W: Human IM-9 lymphoblasts as a model of the growth hormone-insulin-like growth factor axis: Gene expression, and interactions of ligands with receptors and binding proteins. Regul Peptides 1993;48:41–53.
12.
Elmlinger MW, Wimmer K, Biemer E, Blum WF, Ranke MB, Dannecker GE: Insulin-like growth factor binding protein 2 is differentially expressed in leukemic B- and T-cell lines. Growth Regul 1996;6:152–157.
13.
Nyman T, Pekonen F: The expression of insulin-like growth factors and their binding proteins in normal human lymphocytes. Acta Endocrinol 1993;128:168–172.
14.
Gayle CM, Miell JP, McGregor AM, Crossey PA: IGF binding proteins (IGFBPs) in normal human lymphocytes: Endogenous gene expression and changes with lymphocyte stimulation (abstract). 10th Int Congr Endocrinology, San Francisco, 1996, OR33–2.
15.
Gayle CM, Meill JP, McGregor AM, Crossey PA: Endogenous gene expression of IGF binding proteins (IGFBPs) and growth hormone receptor (GHR) in normal human lymphocyte B and T cell subpopulations (abstract). 79th Ann Meet Endocrine Society, Minneapolis, 1997, pp 3–258.
16.
Gayle CM, Crossey PA, McGregor AM, Miell JP: In vitro lymphocyte function in human growth hormone deficiency and excess (abstract). Endocrinol Metab 1997;4(suppl B):182.
17.
Foll JL, Dannecker L, Zehrer C, Hettmer S, Berger J, Elmlinger M, Niethammer D, Ranke MB, Dannecker GE: Activation-dependent expression of the insulin-like growth factor binding protein-2 in human lymphocytes. Immunology 1998;94:173–180.
18.
Elmlinger MW, Sanatani MS, Bell M, Dannecker GE, Ranke MB: Elevated insulin-like growth factor (IGF) binding protein (IGFBP)-2 and IGFBP-4 expression of leukemic T-cells is affected by autocrine/paracrine IGF-II action but not by IGF type I receptor expression. Eur J Endocrinol 1998;138:337–343.
19.
Boyum A: Isolation of lymphocytes, granulocytes and macrophages. Scand J Immunol 1976(suppl 5):9–15.
20.
Auernhammer CJ, Feldmaier H, Nass R, Pachmann K, Strasburger CJ: Insulin-like growth factor I is an independent coregulatory modulator of natural killer (NK) cell activity. Endocrinology 1996;137:5332–5336.
21.
Weber MM, Simmler P, Fottner C, Engelhardt D: Insulin-like growth factor II (IFG-II) is more potent than IGF-I in stimulating cortisol secretion from cultured bovine adrenocortical cells: Interaction with the IGF-I receptor and IGF-binding proteins. Endocrinology 1995;136:3714–3720.
22.
Weber MM, Spöttl G, Gössl C, Engelhardt D: Characterization of human insulin-like growth factor-binding proteins by two-dimensional polyacrylamide gel electrophoresis and Western ligand blot analysis. J Clin Endocrinol Metab 1999;84:1679–1684.
23.
Blum WF, Gallaher B, Ranke MB: An IGFBP-blocked IGF-I RIA that measures what it pretends to measure: IGF-I (abstract). 74th Meet Endocrine Society, 1992, p 968.
24.
Baxter JB, Blalock JE, Weigent DA: Characterization of immunoreactive insulin-like growth factor-I from leukocytes and its regulation by growth hormone. Endocrinology 1991;129:1727–1734.
25.
Sabharwal P, Varma S: Growth hormone synthesized and secreted by human thymocytes acts via insulin-like growth factor I as an autocrine and paracrine growth factor. J Clin Endocrinol Metab 1996;81:2663–2669.
26.
Geffner ME, Bersch N, Lippe BM, Rosenfeld RG, Hintz RL, Golde DW: Growth hormone mediates the growth of T-lymphoblast cell lines via locally generated insulin-like growth factor-I. J Clin Endocrinol Metab 1990;71:464–469.
27.
Hattori N, Shimatsu A, Sugita M, Kumagai S, Imura H: Immunoreactive growth hormone (GH) secretion by human lymphocytes: Augmented release by exogenous GH. Biochem Biophys Res Commun 1990;168:396–401.
28.
Varma S, Sabharwal P, Sheridan JF, Malarkey WB: Growth hormone secretion by human peripheral blood mononuclear cells detected by an enzyme-linked immunoplaque assay. J Clin Endocrinol Metab 1993;76:49–53.
29.
Rapaport R, Stein D, Louzao A, Goode L, Garibaldi L, Stene M: Growth hormone secretion by lymphocytes of growth hormone deficient children (abstract). 10th Int Congr Endocrinology, San Francisco, 1996, pp 1–661.
30.
Muller K, Zak M, Nielsen S, Pedersen FK, de Nully P, Bendtzen K: In vitro cytokine production and phenotype expression by blood mononuclear cells from umbilical cords, children and adults. Pediatr Allergy Immunol 1996;7:117–124.
31.
Katial RK, Sachanandani D, Pinney C, Lieberman MM: Cytokine production in cell culture by peripheral blood mononuclear cells from immunocompetent hosts. Clin Diagn Lab Immunol 1998;5:78–81.
32.
Fan J, Char D, Bagby GJ, Gelato MC, Lang CH: Regulation of insulin-like growth factor-I (IGF-I) and IGF-binding proteins by tumor necrosis factor. Am J Physiol 1995;269:R1204–R1212.
33.
Fan J, Wojnar MM, Theodorakis M, Lang CH: Regulation of insulin-like growth factor (IGF)-I mRNA and peptide and IGF-binding proteins by interleukin-1. Am J Physiol 1996;270:R621–R629.
34.
Thissen JP, Verniers J: Inhibition by interleukin-1 beta and tumor necrosis factor-alpha of the insulin-like growth factor I messenger ribonucleic acid response to growth hormone in rat hepatocyte primary culture. Endocrinology 1997;138:1078–1084.
35.
Hansen JA, Lindberg K, Hilton DJ, Nielsen JH, Billestrup N: Mechanism of inhibition of growth hormone receptor signaling by suppressor of cytokine signaling proteins. Mol Endocrinol 1999;13:1832–1843.
36.
Kovanen PE, Leonard WJ: Inhibitors keep cytokines in check (review). Curr Biol 1999;9:R899–902.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.